VX-745 is a potent inhibitor of p38alpha MAPK (IC50=10nM) with 20-fold selectivity over p38beta and 1000-fold selectivity over closely related kinases, ERK1, MK2 and JNK1-3. p38alpha is a member of the mitogen-activated protein kinase (MAPK) family of serine/threonine protein kinases and is widely expressed in endothelial, immune or inflammatory cells and plays a central role in the regulation of proinflammatory cytokine production including TNF-alpha, IL-1beta and IL-6. VX-745 is an anti-inflammatory agent that blocks IL-1beta and TNF-alpha release in whole blood in vitro with IC50 values of 150 and 180nM, respectively. VX-745 showed anti-inflammatory efficacy in an animal model of rheumatoid arthritis and recently anti-neuroinflammatory potential in prevention of early-stage Alzheimers diseases (AD).
Buffer:
Solid
CAS Number:
[209410-46-8]
* VAT and and shipping costs not included. Errors and price changes excepted
